January 5, 2021 -- Revitope Oncology has entered into a collaboration with Janssen Biotech for the evaluation of Revitope's proprietary T-cell engager technology platform to develop next-generation bispecific antibody therapies.
Revitope's proprietary Precision Guided Antibody Tumor Engager (PrecisionGATE) technology platform exploits coexpressed tumor antigens to enable the development of highly specific cancer drugs with improved safety and efficacy over other conventional immunotherapies. The approach combines a pair of tumor-targeted antibodies with a shared silent T-cell engaging domain that becomes active only when they encounter cancers cells that coexpress both antigens. This technology allows for a highly selective dual-antigen targeting mechanism to elicit a focused gated immune response to tumor cells
Under the terms of the collaboration, Revitope will collaborate with Janssen to conduct a feasibility study of Revitope's technology platform. The agreement was facilitated by Johnson & Johnson Innovation. Financial details of the collaboration were not disclosed.
Copyright © 2021 scienceboard.net